首页> 外文期刊>Modern Pathology >Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
【24h】

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens

机译:基于大系列全组织切片并在小样本中验证的区分肺腺癌和鳞状细胞癌的免疫组织化学算法

获取原文
           

摘要

Immunohistochemistry is increasingly utilized to differentiate lung adenocarcinoma and squamous cell carcinoma. However, detailed analysis of coexpression profiles of commonly used markers in large series of whole-tissue sections is lacking. Furthermore, the optimal diagnostic algorithm, particularly the minimal-marker combination, is not firmly established. We therefore studied whole-tissue sections of resected adenocarcinoma and squamous cell carcinoma (n=315) with markers commonly used to identify adenocarcinoma (TTF-1) and squamous cell carcinoma (p63, CK5/6, 34βE12), and prospectively validated the devised algorithm in morphologically unclassifiable small biopsy/cytology specimens (n=38). Analysis of whole-tissue sections showed that squamous cell carcinoma had a highly consistent immunoprofile (TTF-1-negative and p63/CK5/6/34βE12-diffuse) with only rare variation. In contrast, adenocarcinoma showed significant immunoheterogenetity for all ‘squamous markers’ (p63 (32%), CK5/6 (18%), 34βE12 (82%)) and TTF-1 (89%). As a single marker, only diffuse TTF-1 was specific for adenocarcinoma whereas none of the ‘squamous markers,’ even if diffuse, were entirely specific for squamous cell carcinoma. In contrast, coexpression profiles of TTF-1/p63 had only minimal overlap between adenocarcinoma and squamous cell carcinoma, and there was no overlap if CK5/6 was added as a third marker. An algorithm was devised in which TTF-1/p63 were used as the first-line panel, and CK5/6 was added for rare indeterminate cases. Prospective validation of this algorithm in small specimens showed 100% accuracy of adenocarcinoma vs squamous cell carcinoma prediction as determined by subsequent resection. In conclusion, although reactivity for ‘squamous markers’ is common in lung adenocarcinoma, a two-marker panel of TTF-1/p63 is sufficient for subtyping of the majority of tumors as adenocarcinomas vs squamous cell carcinoma, and addition of CK5/6 is needed in only a small subset of cases. This simple algorithm achieves excellent accuracy in small specimens while conserving the tissue for potential predictive marker testing, which is now an essential consideration in advanced lung cancer specimens.
机译:免疫组织化学越来越多地用于区分肺腺癌和鳞状细胞癌。然而,缺乏对大系列全组织切片中常用标志物共表达谱的详细分析。此外,还没有确定最佳的诊断算法,尤其是最小标记组合。因此,我们使用通常用于鉴定腺癌(TTF-1)和鳞状细胞癌(p63,CK5 / 6、34βE12)的标记物对切除的腺癌和鳞状细胞癌(n = 315)的全组织切片进行了研究,并对其进行了前瞻性验证形态学上无法分类的小型活检/细胞学标本中的算法(n = 38)。对整个组织切片的分析表明,鳞状细胞癌具有高度一致的免疫特征(TTF-1阴性和p63 / CK5 / 6 /34βE12扩散),只有极少的变异。相比之下,腺癌对所有“鳞状标志物”(p63(32 %),CK5 / 6(18 %),34βE12(82 %))和TTF-1(89 %)均显示出明显的免疫异质性。作为单一标记,只有弥漫性TTF-1特异性针对腺癌,而即使是弥漫性的“鳞状标记”都没有完全针对鳞状细胞癌。相反,TTF-1 / p63的共表达谱在腺癌和鳞状细胞癌之间只有最小的重叠,如果添加CK5 / 6作为第三个标记,则不会重叠。设计了一种算法,其中将TTF-1 / p63作为一线专家组,并为罕见的不确定情况添加了CK5 / 6。该算法在小样本中的前瞻性验证显示,腺癌与鳞状细胞癌预测的准确性为100%(由随后的切除决定)。总之,尽管在肺腺癌中“鳞状标志物”的反应性很常见,但TTF-1 / p63的两个标志物组足以区分大多数肿瘤,如腺癌和鳞状细胞癌,而添加CK5 / 6是仅在一小部分情况下需要。这种简单的算法可在小样本中实现出色的准确性,同时保留组织用于潜在的预测标记物测试,这现在已成为晚期肺癌样本中的重要考虑因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号